Molecule Information
General Information of the Molecule (ID: Mol02120)
Name |
Autolysins enzymes (ALTE)
,Staphylococcus aureus
|
||||
---|---|---|---|---|---|
Synonyms |
altE
Click to Show/Hide
|
||||
Molecule Type |
Protein
|
||||
Gene Name |
altE
|
||||
Click to Show/Hide the Complete Species Lineage | |||||
Type(s) of Resistant Mechanism of This Molecule
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Drug
Approved Drug(s)
1 drug(s) in total
Diclofenac
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Disease Class: Staphylococcus aureus infection | [1] | |||
Sensitive Disease | Staphylococcus aureus infection [ICD-11: 1B54.0] | |||
Sensitive Drug | Diclofenac | |||
Molecule Alteration | Expression | Down-regulation |
||
Experimental Note | Discovered Using In-vivo Testing Model | |||
Cell Pathway Regulation | mecA/blaZ pathway | Activation | hsa01501 | |
In Vivo Model | Murine skin and soft tissue infection model | Mus musculus | ||
Experiment for Molecule Alteration |
Gene expression analysis; Cellular ATP level assay; Ethidium bromide efflux inhibition assay | |||
Experiment for Drug Resistance |
CCK-8 assay | |||
Mechanism Description | High-dose diclofenac can inhibit the growth of MRSA, and does not easily induce drug-resistant mutations after continuous passage. Low-doses diclofenac can resensitize bacteria to beta-lactams, which help to circumvent drug resistance and improve the antibacterial efficacy of conventional antibiotics. Diclofenac can reduce the expression of genes and proteins associated with beta-lactam resistance, low dose diclofenac can inhibit MRSA antibiotic resistance via the mecA/blaZ pathway and related biofilms in implants. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.